Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A method to comprehensively identify germline SNVs, INDELs and CNVs from whole exome sequencing data of BRCA1/2 negative breast cancer patients.
Bianchi A, Zelli V, D'Angelo A, Di Matteo A, Scoccia G, Cannita K, Dimas AS, Glentis S, Zazzeroni F, Alesse E, Di Marco A, Tessitore A. Bianchi A, et al. Among authors: cannita k. NAR Genom Bioinform. 2024 Apr 17;6(2):lqae033. doi: 10.1093/nargab/lqae033. eCollection 2024 Jun. NAR Genom Bioinform. 2024. PMID: 38633426 Free PMC article.
[Oxaliplatin: preclinical in vitro studies].
Marchetti P, Carlo G, Cappellini A, Porzio G, Ricevuto E, Cannita K, Ficorella C. Marchetti P, et al. Among authors: cannita k. Tumori. 2001 Nov-Dec;87(6):A22-4. Tumori. 2001. PMID: 11995699 Review. Italian. No abstract available.
[The adjuvant therapy of colonic carcinoma in old age].
Ficorella C, Cannita K, Ricevuto E, Porzio G, Trapasso T, De Galitiis F, Gallà DA, Morese R, D'Addario M, Marchetti P. Ficorella C, et al. Among authors: cannita k. Minerva Med. 1999 Jul-Aug;90(7-8):232-3. Minerva Med. 1999. PMID: 10719426 Italian. No abstract available.
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.
Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C. Cortellini A, et al. Among authors: cannita k. J Immunother Cancer. 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y. J Immunother Cancer. 2019. PMID: 30813970 Free PMC article.
[Familiarity and heredity of tumors in function of an early surgical therapeutic approach].
Ricevuto E, Di Rocco ZC, Cianci G, Bisegna R, Casilli F, De Galitiis F, Cannita K, Calista F, Porzio G, Bafile A, Vicentini R, Resta V, De Rubeis G, Martinotti S, Ficorella C, Marchetti P. Ricevuto E, et al. Among authors: cannita k. Suppl Tumori. 2002 May-Jun;1(3):S89-91. Suppl Tumori. 2002. PMID: 12415797 Review. Italian. No abstract available.
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S. Cortellini A, et al. Among authors: cannita k. Clin Lung Cancer. 2019 Jul;20(4):237-247.e1. doi: 10.1016/j.cllc.2019.02.006. Epub 2019 Feb 21. Clin Lung Cancer. 2019. PMID: 30885550
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, Bracarda S, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierto PA. Cortellini A, et al. Among authors: cannita k. Eur J Cancer. 2020 Mar;128:17-26. doi: 10.1016/j.ejca.2019.12.031. Epub 2020 Mar 5. Eur J Cancer. 2020. PMID: 32109847
105 results